DDInter593 DDInter927
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Doxepin {u} (Compound) resembles {v} (Compound) Thiothixene
Doxepin {u} (Compound) resembles {v} (Compound) Imipramine
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Cyclobenzaprine
Doxepin {u} (Compound) binds {v} (Gene) HTR2A
Doxepin {u} (Compound) upregulates {v} (Gene) MCOLN1
Doxepin {u} (Compound) palliates {v} (Disease) atopic dermatitis
Doxepin {u} (Compound) downregulates {v} (Gene) FAM69A
Doxepin {u} (Compound) causes {v} (Side Effect) Elevated mood
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Doxepin (Compound) resembles Thiothixene (Compound)
Doxepin (Compound) resembles Imipramine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine
Doxepin (Compound) binds HTR2A (Gene)
Doxepin (Compound) upregulates MCOLN1 (Gene)
Doxepin (Compound) palliates atopic dermatitis (Disease)
Doxepin (Compound) downregulates FAM69A (Gene)
Doxepin (Compound) causes Elevated mood (Side Effect)